Enoxaparin injection for the treatment of high-risk patients with non-ST elevation acute coronary syndrome

References

• AntmanEMCohenMAssessment of the treatment effect of enoxaparin for unstable angina/non-Q-wave myocardial infarction : TIMI 11B-ESSENCE meta-analysisCirculation1999100151602810517730
   PubMedGoogle Scholar
• AntmanEMMcCabeCHEnoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction: results of the Thrombolysis In Myocardial Infarction (TIMI) 11B TrialCirculation1999100159360110517729
   PubMed Web of Science ®Google Scholar
• BhattDLLeeBISafety of concomitant therapy with eptifibatide and enoxaparin in patients undergoing percutaneous coronary intervention: Results of the coronary revascularization using integrilin and single bolus enoxaparin studyJ Am Coll Cardiol20034120512570939
   PubMed Web of Science ®Google Scholar
• BhattDLRoeMTUtilization of early invasive management strategies for high-risk patients with non-ST-segment elevation acute coronary syndromes: results from the CRUSADE Quality Improvement InitiativeJAMA2004292209610415523070
   PubMed Web of Science ®Google Scholar
• BittlJAChaitmanBRBivalirudin versus heparin during coronary angioplasty for unstable or postinfarction angina: Final report reanalysis of the Bivalirudin Angioplasty StudyAm Heart J2001142952911717596
   PubMed Web of Science ®Google Scholar
• BlazingMAde LemosJASafety and efficacy of enoxaparin vs unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes who receive tirofiban and aspirin: a randomized controlled trialJAMA2004292556415238591
   PubMed Web of Science ®Google Scholar
• BraunwaldEAntmanEMACC/AHA Guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction—2002: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Unstable Angina)Circulation2002106189390012356647
   PubMed Web of Science ®Google Scholar
• CannonCPWeintraubWSComparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein iib/iiia inhibitor tirofiban. 10.1056/NEJM200106213442501 N Engl J Med200134418798711419424
   PubMed Web of Science ®Google Scholar
• ChenJA randomized comparative study of using enoxaparin instead of unfractionated heparin in the intervention treatment of coronary heart diseaseChin Med J (Engl)2006119355916542576
   PubMed Web of Science ®Google Scholar
• CohenMDemersCA comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery diseaseN Engl J Med1997337447529250846
   PubMed Web of Science ®Google Scholar
• CohenMTherouxPRandomized double-blind safety study of enoxaparin versus unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes treated with tirofiban and aspirin: The ACUTE II studyAm Heart J2002144470712228784
   PubMed Web of Science ®Google Scholar
• de LemosJABlazingMAEnoxaparin versus unfractionated heparin in patients treated with tirofiban, aspirin and an early conservative initial management strategy: results from the A phase of the A-to-Z trialEur Heart J20042516889415451146
   PubMed Web of Science ®Google Scholar
• de WinterRJWindhausenFEarly invasive versus selectively invasive management for acute coronary syndromesN Engl J Med2005353109510416162880
   PubMed Web of Science ®Google Scholar
• EikelboomJWAnandSSUnfractionated heparin and low-molecular-weight heparin in acute coronary syndrome without ST elevation: a meta-analysisLancet200035519364210859038
   PubMed Web of Science ®Google Scholar
• FRagmin Fast Revascularisation during In Stability in Coronary artery disease (FRISC II), ILong-term low-molecular-mass heparin in unstable coronary-artery disease: FRISC II prospective randomised multicentre studyLancet1999354701710475180
   PubMed Web of Science ®Google Scholar
• FRagmin and Fast Revascularisation during InStability in Coronary artery disease (FRISC II), IInvasive compared with non-invasive treatment in unstable coronary-artery disease: FRISC II prospective randomised multicentre studyLancet19993547081510475181
   PubMed Web of Science ®Google Scholar
• FergusonJJAntmanEMCombining enoxaparin and glycoprotein IIb/IIIa antagonists for the treatment of acute coronary syndromes: final results of the National Investigators Collaborating on Enoxaparin-3 (NICE-3) studyAm Heart J20031466283414564315
   PubMed Web of Science ®Google Scholar
• FoxKPoole-WilsonP5-year outcome of an interventional strategy in non-ST-elevation acute coronary syndrome: the British Heart Foundation RITA 3 randomised trialLancet20053669142016154018
   PubMed Web of Science ®Google Scholar
• FusterVBadimonLThe pathogenesis if coronary artery disease and the acute coronary syndromesN Engl J Med1992326242501727977
   PubMed Web of Science ®Google Scholar
• GibsonCMMorrowDAA randomized trial to evaluate the relative protection against post-percutaneous coronary intervention microvascular dysfunction, ischemia, and inflammation among antiplatelet and antithrombotic agents: The PROTECT-TIMI-30 TrialJ Am Coll Cardiol20064723647316781360
   PubMed Web of Science ®Google Scholar
• GoodmanSGFitchettDRandomized evaluation of the safety and efficacy of enoxaparin versus unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes receiving the glycoprotein iib/iiia inhibitor eptifibatideCirculation20031072384412538422
   PubMed Web of Science ®Google Scholar
• KleinWKraxnerWPatterns of use of heparins in ACS. Correlates and hospital outcomes: the Global Registry of Acute Coronary Events (GRACE)Thromb Haemost2003905192712958622
   PubMed Web of Science ®Google Scholar
• KleinWBuchwaldAComparison of low-molecular-weight heparin with unfractionated heparin acutely and with placebo for 6 weeks in the management of unstable coronary artery disease: Fragmin in Unstable Coronary Artery Disease Study (FRIC)Circulation1997966189236418
   PubMed Web of Science ®Google Scholar
• KongDFTopolEJClinical Outcomes of bivalirudin for ischemic heart diseaseCirculation199910020495310562259
   PubMed Web of Science ®Google Scholar
• LincoffAMBittlJABivalirudin and provisional glycoprotein iib/iiia blockade compared with heparin and planned glycoprotein iib/iiia blockade during percutaneous coronary intervention: REPLACE-2 Randomized TrialJAMA20032898536312588269
   PubMed Web of Science ®Google Scholar
• MICHELANGELO OASIS 5 Steering CDesign and rationale of the MICHELANGELO Organization to Assess Strategies in Acute Ischemic Syndromes (OASIS)-5 trial program evaluating fondaparinux, a synthetic factor Xa inhibitor, in patients with non-ST-segment elevation acute coronary syndromesAm Heart J20051501107.e11107.e1016338245
   PubMed Web of Science ®Google Scholar
• MontalescotGWhiteHDEnoxaparin versus unfractionated heparin in elective percutaneous coronary interventionN Engl J Med200635510061716957147
   PubMed Web of Science ®Google Scholar
• NeumannF-JKastratiAEvaluation of prolonged antithrombotic pretreatment (“cooling-off” strategy) before intervention in patients with unstable coronary syndromes: a randomized controlled trialJAMA20032901593914506118
   PubMed Web of Science ®Google Scholar
• PetersenJLMahaffeyKWEfficacy and bleeding complications among patients randomized to enoxaparin or unfractionated heparin for antithrombin therapy in non-ST-segment elevation acute coronary syndromes: a systematic overviewJAMA2004292899615238596
   PubMed Web of Science ®Google Scholar
• SinghKRoeMLow-molecular-weight heparin compared with unfractionated heparin for patients with non-ST-segment elevation acute coronary syndromes treated with glycoprotein IIb/IIIa inhibitors: Results from the CRUSADE initiativeJ Thromb Thrombolysis2006212112016683212
   PubMed Web of Science ®Google Scholar
• StoneGWBertrandMAcute Catheterization and Urgent Intervention Triage strategY (ACUITY) trial: Study design and rationaleAm Heart J20041487647515523305
   PubMed Web of Science ®Google Scholar
• SYNERGY Trial InvestigatorsEnoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trialJAMA2004292455415238590
   PubMed Web of Science ®Google Scholar
• The Fifth Organization to Assess Strategies in Acute Ischemic Syndromes InvestigatorsComparison of fondaparinux and enoxaparin in acute coronary syndromesN Engl J Med200635414647616537663
   PubMed Web of Science ®Google Scholar
• The Frax.I.S. Study GroupComparison of two treatment durations (6 days and 14 days) of a low molecular weight heparin with a 6-day treatment of unfractionated heparin in the initial management of unstable angina or non-Q wave myocardial infarction: FRAX.I.S. (FRAxiparine in Ischaemic Syndrome)Eur Heart J19992015536210529323
   PubMed Web of Science ®Google Scholar
• WeitzJILow-molecular-weight heparinsN Engl J Med1997337688999278467
   PubMed Web of Science ®Google Scholar
• ZeymerUGittAClinical benefit of enoxaparin in patients with high-risk acute coronary syndromes without ST elevations in clinical practiceAm J Cardiol200698192216784913
   PubMed Web of Science ®Google Scholar